News & Events – Page 16 – Sumitovant

Select Company

August 06, 2019Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for First Fiscal Quarter Ended June 30, 2019
August 05, 2019Altavant Sciences Initiates Phase 2a Study of Rodatristat Ethyl in Pulmonary Arterial Hypertension
July 23, 2019Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and Positive Results from Bioequivalence Study
July 22, 2019Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, July 23rd to Discuss Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and from Bioequivalence Study
July 10, 2019Myovant Sciences and Evidation Health Announce Partnership and Launch Digital Insights Study on Menstruation
June 13, 2019Urovant Sciences Reports Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019
June 06, 2019Urovant Sciences to Report Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019
June 05, 2019Enzyvant Announces FDA Acceptance of Biologics License Application (BLA) and Priority Review Status for RVT-802, a Novel Investigational Tissue-Based Regenerative Therapy for Pediatric Congenital Athymia
June 04, 2019Myovant Sciences to Present at Upcoming June Investor Conferences
June 03, 2019Urovant Sciences to Present at Annual Roivant Pipeline Day
« Previous 1 … 14 15 16 17 18 19 Next »